Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Condition: Diabetes Mellitus, Type 2 Interventions: Drug: ITCA 650 20/60 mcg/day; Drug: Empagliflozin (oral); Drug: Glimepiride (oral) Sponsor: Intarcia Therapeutics Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Empagliflozin | Endocrinology | Fortamet | Glimepiride | Jardiance | Metformin | Research